<Header>
<FileStats>
    <FileName>20161117_10-Q-A_edgar_data_1053369_0001144204-16-135163_1.txt</FileName>
    <GrossFileSize>66527</GrossFileSize>
    <NetFileSize>18291</NetFileSize>
    <ASCII_Embedded_Chars>0</ASCII_Embedded_Chars>
    <HTML_Chars>40185</HTML_Chars>
    <XBRL_Chars>0</XBRL_Chars>
    <XML_Chars>0</XML_Chars>
    <N_Tables>9</N_Tables>
    <N_Exhibits>3</N_Exhibits>
</FileStats>
<SEC-Header>
0001144204-16-135163.hdr.sgml : 20161117
<ACCEPTANCE-DATETIME>20161117160206
ACCESSION NUMBER:		0001144204-16-135163
CONFORMED SUBMISSION TYPE:	10-Q/A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20120930
FILED AS OF DATE:		20161117
DATE AS OF CHANGE:		20161117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELITE PHARMACEUTICALS INC /NV/
		CENTRAL INDEX KEY:			0001053369
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				223542636
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15697
		FILM NUMBER:		162004965

	BUSINESS ADDRESS:	
		STREET 1:		165 LUDLOW AVENUE
		CITY:			NORTHVALE
		STATE:			NJ
		ZIP:			07647
		BUSINESS PHONE:		2017502646

	MAIL ADDRESS:	
		STREET 1:		165 LUDLOW AVENUE
		CITY:			NORTHVALE
		STATE:			NJ
		ZIP:			07647

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ELITE PHARMACEUTICALS INC /DE/
		DATE OF NAME CHANGE:	19980121

</SEC-Header>
</Header>

 0001144204-16-135163.txt : 20161117

10-Q/A
 1
 v453381_10qa.htm
 FORM 10-Q/A

U.S. SECURITIES AND EXCHANGE COMMISSION 

 Washington, D.C. 20549 

 FORM 10-Q/A 

   (Amendment
No. 1)   

or 

For the transition period ended                                           to 

ELITE PHARMACEUTICALS, INC.   
 
      (Exact name of registrant as specified in its charter)   

Nevada   
         
       22-3542636    
 
      (State or other jurisdiction of incorporation or organization)  
       
      (I.R.S. Employer Identification No.)   

(Former name, former
address and former fiscal year, if changed since last report) 

Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. 

  Yes
  x  
No      

Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (   232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post
such files).   

  Yes
  x  
No      

Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of  accelerated filer and
large accelerated filer  in Rule 12b-2 of the Exchange Act. (Check one): 

Large Accelerated filer       
      Accelerated Filer   x  
      Non-Accelerated Filer       
       Smaller Reporting Company        

Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). 

  Yes
     
No   x  

Indicate the number of shares outstanding of
each of the issuer s classes of common stock, as of the latest practicable date. As of November 8, 2012 the issuer had outstanding
350,337,260 shares of common stock, $0.001 par value (exclusive of 100,000 shares held in treasury). 

EXPLANATORY NOTE  

This Amendment No. 1 on Form 10-Q/A ( Amendment
No. 1 ) amends our Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 that was filed with the Securities
and Exchange Commission, or SEC, on November 14, 2012 (the  Original Filing ). We are filing this Amendment No. 1 solely
for the purpose of attaching as Exhibit 10.6 an unredacted copy of the September 21, 2012 Letter Agreement between Elite Pharmaceuticals,
Inc. (the  Company ) and ThePharmaNetwork, LLC. 

As required by Rule 12b-15 under the Securities
Exchange Act of 1934, as amended, Item 6 of Part II of the Original Filing has been amended to contain currently dated certifications
from our Chief Executive Officer and Chief Financial Officer. The currently dated certifications are attached hereto as Exhibits
31.1 and 31.2. Because no financial statements of Elite Pharmaceuticals, Inc. are contained in this Amendment No. 1, we are not
including certifications pursuant to 18 U.S.C. 1350. 

No other changes, other than described above, are made to the Original
Filing other than to update the cover page of the Original Filing. Unless expressly stated, this Amendment No. 1 does not reflect
events occurring after the filing of the Original Filing, nor does it modify or update in any way the disclosures contained in
the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with our Original Filing and our other filings
made with the SEC subsequent to the filing of the Original Filing. 

ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES  

  INDEX  

PART II   OTHER INFORMATION   

PART II.    OTHER INFORMATION  

Item 6.      Exhibits   

The exhibits listed in
the index below are filed as part of this report. 

* Filed herewith. 

1   

SIGNATURES  

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment No. 1 to be signed on its behalf by the undersigned
thereunto duly authorized. 

ELITE PHARMACEUTICALS, INC.   

November 16, 2016 
     By: 
     /s/ Nasrat Hakim  

Nasrat Hakim 
         Chief Executive Officer, President and Chairman of the
Board of Directors (Principal Executive Officer)   

November 16, 2016 
     By: 
     /s/ Carter J. Ward  

Carter J. Ward 
         Chief Financial Officer, Treasurer and Secretary (Principal
Financial and Accounting Officer)    

2   

<EX-10.6>
 2
 v453381_ex10-6.htm
 EXHIBIT 10.6

Exhibit 10.6  

September 21, 2012 

Elite Pharmaceuticals, Inc. 

 165 Ludlow Avenue 

 Northvale, NJ 07647 

Attention: Chris Dick 

    President 

Re:           First Amendment 

 TPN-Elite Manufacturing and Supply Agreement
dated June 23, 2011 

Gentlemen: 

ThePharmaNetwork, LLC, a New Jersey limited
liability company and its wholly owned subsidiary, Ascend Laboratories, LLC (together  TPN ), and Elite Pharmaceuticals,
Inc. and Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.), both Delaware corporations (together  ELITE )
are parties to certain manufacturing and supply agreement effective as of June 23, 2011 (the  Agreement ). All capitalized
terms used without definition in this letter agreement have the respective meanings provided in the Agreement. 

Effective as of the date of this letter agreement,
the parties agree that sections 7.1 9.3. 2.7 and 3.3 of, and Exhibit A attached to, the Agreement are amended in their entirety
and, as amended, read as follows: 

Section 7.1.       Term. The initial term (the
 Initial Term ) of this Agreement shall commence on the Effective Date and shall continue until December 31, 2014;
thereafter, the term of this Agreement shall be extended for one (1) year terms (each a  Renewal Term ) upon the mutual
written agreement of the Parties entered into at least six (6) months prior to the expiration of the Initial Term or a Renewal
Term.   

Section 9.3.       Notices . Except as otherwise
specifically provided, any notice or other documents to be given under this Manufacturing Agreement shall be in writing and shall
be deemed to have been duly given if sent by registered mail, nationally recognized overnight delivery service or facsimile transmission
to a Party or delivered in person to a Party at the address or facsimile number set out below for such Party or such other address
as the Party may from time to time designate by written notice to the other:   

If to ELITE: Elite Pharmaceuticals, Inc.   

165 Ludlow Avenue   

  Northvale, NJ 07647   

  Attention: President   

  Facsimile: 201-750-2755   

with a copy to: Silverman Sclar Shin   Byrne PLCC  

  381 Park Avenue South  

  New York, New York 10016   

Attn: Richard Feiner   

  Facsimile: 917-720-0863   

If to TPN: ThePharmaNetwork, LLC   

  180 Summit Avenue, Suite 200Montvale, NJ 07645   

  Attention: George Solomon, COO  

  Facsimile: 201-476-1987   

1   

with a copy to:   

  ThePharmaNetwork, LLC  

  180 Summit Avenue, Suite 200  

  Montvale, NJ 07645  

  Attention: Allen Bagatsing, Esq. /Chief Legal
Counsel   

  Facsimile: 201-476-1987  

Any such notice provided pursuant to this Section 9.3 shall be
deemed to have been received by the addressee five business days following the date of dispatch of the notice or other document
by mail or, where the notice or other document is sent by overnight delivery service, by hand or is given by facsimile, simultaneously
with the transmission or delivery. To prove the giving of a notice or other document it shall be sufficient to show that it was
dispatched. Either Party may change its address at which notice is to be received by written notice provided pursuant to this Section
9.3.   

Section 3.3.      Invoicing and Payment. Payment
terms by TPN for Product supplied by ELITE hereunder meeting Product Specifications shall be net 30 days by check or wire transfer,
and shall be made without set-off and free and clear of, and without any deduction or withholding for or on account of any taxes,
duties, levies, fees or charges, except as otherwise permitted under this Manufacturing Agreement. Product shall be invoiced no
sooner than the date of shipment by ELITE. If TPN disputes any invoice, TPN shall notify ELITE that it disputes the accuracy of
such invoice specifying in particularity such inaccuracy. TPN and ELITE shall make good faith efforts to resolve any disputes within
fifteen (15) days thereafter and subject to Section 7.2 a (iii). Any amounts that are disputed shall be due upon the resolution
of such dispute.   

Section 2.7.       Delays. During the Term
of this Manufacturing Agreement, if ELITE is not able to timely meet Product orders submitted by TPN pursuant to Section 2.2, ELITE
shall promptly notify TPN of the reason for the delay and the date delivery of Product is expected to occur. If shipment is delayed
more than ten (10) business days beyond the date of delivery for reasons other than API supply (including DEA quota issues), then
ELITE shall be responsible for any and all customer bill back penalty actually incurred and documented by TPN to be paid by ELITE
within fifteen (15) days from receipt of such invoice.   

2   

Exhibit A- Product and Purchase Price and Minimum Annual Volume
Requirements 

1. All bottles manufactured in excess of 500,000 bottles each calendar
year, shall be at a firm cost per bottle exclusive of API FOB Elite of $1.88. 

NOTES: The purchase price includes all costs except API cost
which is the obligation of TPN and is firm during the term of the Agreement.  

ELITE shall produce Product in batch sizes between 2,000 bottles
to 10,000 bottles per batch. Elite will begin with the smaller batch sizes and increase batch size as necessary. Starting no later
than January, 2013 orders shall be manufactured based on a batch size of 10,000 bottles.   

Provided that TPN will give Elite 90 days advance notice, Elite
shall accept and be able to guarantee the manufacturing of up to 1,500,000 bottles/year.  

During the 12 months ending December 31, 2014 and upon TPN s
written request, Elite must be able to manufacture up to 2,000,000 bottles/year.  

ELITE may also, from time to time, subcontract to Epic Pharma,
LLC for bottling of batches but at its earliest, will transfer the packaging operations to its own facility.  

Except as expressly modified by this letter agreement, the parties
agree that the Agreement will continue in full force and effect in accordance with its terms. 

If the foregoing correctly sets forth our agreement and understanding,
please execute the enclosed counterpart of this letter agreement and return the executed counterpart to the undersigned at your
convenience. 

(Space left intentionally blank, signature
page follows)  

3   

THEPHARMANETWORK, LLC    

By   
      /s/ George Solomon   
 
      Name:    
      George Solomon   
 
      Title:  
      COO   

Accepted and agreed as of this September 21, 2012 

ELITE PHARMACEUTICALS, INC.    

By  
      /s/ Chris Dick   
 
      Name:   
      Chris Dick   
 
      Title:  
      President   

4   

</EX-10.6>

<EX-31.1>
 3
 v453381_ex31-1.htm
 EXHIBIT 31.1

Exhibit 31.1   

  CERTIFICATION  

I, Nasrat Hakim, certify that: 

1.  I have reviewed this Amendment No. 1 to the Quarterly Report
on Form 10-Q for the quarter ended September 30, 2012 of Elite Pharmaceuticals, Inc. (the  Registrant ); 

2.  Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report; 

3.  Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the Registrant as of, and for, the periods presented in this report; 

4.  The Registrant s other certifying officer and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant
and have: 

(a)  Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared; 

(b)  Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles; 

(c)  Evaluated the effectiveness of the Registrant s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and 

(d)  Disclosed in this report any change in the Registrant s
internal control over financial reporting that occurred during the Registrant s most recent fiscal quarter (the Registrant's
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the Registrant s internal control over financial reporting. 

5.  The Registrant s other certifying officer and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant s auditors
and the audit committee of the Registrant s board of directors (or persons performing the equivalent functions): 

(a)  All significant deficiencies and material weaknesses in
the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant s
ability to record, process, summarize and report financial information; and 

(b)  Any fraud, whether or not material, that involves management
or other employees who have a significant role in the Registrant s internal control over financial reporting. 

Date: November 16, 2016  
      /s/ Nasrat
    Hakim      

Nasrat Hakim  

Chief Executive Officer  

(Principal Executive Officer)  

</EX-31.1>

<EX-31.2>
 4
 v453381_ex31-2.htm
 EXHIBIT 31.2

Exhibit 31.2  

 CERTIFICATION 

I, Carter J. Ward, certify that: 

1.  I have reviewed this Amendment No. 1 to the Quarterly Report
on Form 10-Q for the quarter ended September 30, 2012 of Elite Pharmaceuticals, Inc. (the  Registrant ); 

2.  Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report; 

3.  Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the Registrant as of, and for, the periods presented in this report; 

4.  The Registrant s other certifying officer and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant
and have: 

(a)  Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared; 

(b)  Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles; 

(c)  Evaluated the effectiveness of the Registrant s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and 

(d)  Disclosed in this report any change in the Registrant s
internal control over financial reporting that occurred during the Registrant s most recent fiscal quarter (the Registrant's
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the Registrant s internal control over financial reporting. 

5.  The Registrant s other certifying officer and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant s auditors
and the audit committee of the Registrant s board of directors (or persons performing the equivalent functions): 

(a)  All significant deficiencies and material weaknesses in
the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant s
ability to record, process, summarize and report financial information; and 

(b)  Any fraud, whether or not material, that involves management
or other employees who have a significant role in the Registrant s internal control over financial reporting. 

Date: November 16, 2016  
      /s/
    Carter J. Ward     

Carter J. Ward  

Chief Financial Officer  

( Principal Accounting and Financial
    Officer)   

</EX-31.2>

